Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed / Refractory Cancer Indications

Multiple Myeloma

This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed / refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), and higher risk myelodysplastic syndrome (HR-MDS). Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.
Multiple Myeloma
I/II
Mohan, Sanjay
NCT02649790
VICCHEM15112

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: